Product/Composition:- | Teneligliptin Tablets |
---|---|
Strength:- | 20 mg, 40mg |
Form:- | Tablets |
Reference Brands:- | Tenelia®, Teneza®, and Teneliget®(India & Japan/ Asia) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Teneligliptin is a DPP-4 inhibitor that increases incretin hormone levels, enhancing insulin secretion and reducing glucagon in a glucose-dependent manner. It improves glycemic control in type 2 diabetes with a low risk of hypoglycemia, is weight-neutral, and offers once-daily oral dosing—making it effective and patient-friendly.
Teneligliptin, a DPP-4 inhibitor used for type 2 diabetes, is not approved by the U.S. FDA or the European Medicines Agency (EMA). It is currently not available in the US or EU markets due to the absence of regulatory submissions or market authorization. Teneligliptin is, however, widely approved in Asian countries like Japan and India. For companies seeking to register or introduce Teneligliptin in regulated markets, thorough clinical data, CTD dossiers, and compliance with ICH guidelines are essential. For regulatory consulting, dossier preparation, or global sourcing, visit PharmaTradz.com.